Novel chemical scaffolds against Schistosoma mansoni discovered by combi-QSAR, virtual screening, and confirmed by experimental evaluation with automated imaging

Background: Schistosomiasis is a neglected tropical disease that affects millions of people worldwide. Thioredoxin glutathione reductase of Schistosoma mansoni ( Sm TGR) is a validated drug target that plays a crucial role in the redox homeostasis of the parasite. We report the discovery of new chemical scaffolds against S. mansoni using a combi-QSAR approach followed by virtual screening of a commercial database and confirmation of top ranking compounds by in vitro experimental evaluation with automated imaging of schistosomula and adult worms. Results: We constructed 2D and 3D quantitative structure–activity relationship (QSAR) models using a series of oxadiazoles-2-oxides reported in the literature as Sm TGR inhibitors and combined the best models in a consensus QSAR model. This model was used in a virtual screen of a commercial database and allowed the identification of ten new potential Sm TGR inhibitors. The latter were screened on schistosomula and two active compounds were further evaluated on adult worms. Conclusions: We succeed to develop predictive virtual screening tool based on 2D and 3D QSAR models. After prioritizing virtual screening hits, high activity of two compounds representing new chemical scaffolds, 4-nitro-3,5-bis(1-nitro-1 H -pyrazol-4-yl)-1 H -pyrazole and 3-nitro-4-{[(4-nitro-1,2,5-oxadiazol-3-yl)oxy]methyl}-1,2,5-oxadiazole (LabMol-17 and LabMol-19, respectively) was experimentally validated. These compounds will be subjects for additional testing and, if necessary, modification to serve as new schistosomicidal agents.

[1]  Andreas Bender,et al.  Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. , 2016, Drug discovery today.

[2]  P. Hotez,et al.  New Vaccines for the World's Poorest People. , 2016, Annual review of medicine.

[3]  C. Andrade,et al.  Natural Products as Leads in Schistosome Drug Discovery , 2015, Molecules.

[4]  Bruno J. Neves,et al.  In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni , 2015, PLoS neglected tropical diseases.

[5]  Jianmei Yang,et al.  Inhibitory Effects and Analysis of RNA Interference on Thioredoxin Glutathione Reductase Expression in Schistosoma japonicum , 2014, The Journal of parasitology.

[6]  Vinicius M Alves,et al.  Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. , 2014, Current topics in medicinal chemistry.

[7]  C. King,et al.  Human schistosomiasis , 2014, The Lancet.

[8]  C. Andrade,et al.  3D-QSAR approaches in drug design: perspectives to generate reliable CoMFA models. , 2014, Current computer-aided drug design.

[9]  C. Andrade,et al.  In silico prediction of drug metabolism by P450. , 2014, Current drug metabolism.

[10]  Alexander Tropsha,et al.  Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.

[11]  J. Keiser,et al.  Orally Active Antischistosomal Early Leads Identified from the Open Access Malaria Box , 2014, PLoS neglected tropical diseases.

[12]  C. Andrade,et al.  New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches. , 2013, Current pharmaceutical design.

[13]  Carolina Horta Andrade,et al.  Advances in methods for predicting phase I metabolism of polyphenols. , 2014, Current drug metabolism.

[14]  Q. Bickle,et al.  Automated Imaging and other developments in whole‐organism anthelmintic screening , 2013, Parasite immunology.

[15]  Kunal Roy,et al.  Some case studies on application of “rm2” metrics for judging quality of quantitative structure–activity relationship predictions: Emphasis on scaling of response data , 2013, J. Comput. Chem..

[16]  Carolina H Andrade,et al.  Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? , 2013, Current topics in medicinal chemistry.

[17]  Carolina H Andrade,et al.  Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches. , 2013, Bioorganic & medicinal chemistry letters.

[18]  William L Jorgensen,et al.  Challenges for academic drug discovery. , 2012, Angewandte Chemie.

[19]  You-sheng Liang,et al.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review , 2012, Parasitology Research.

[20]  Jürgen Bajorath,et al.  Chemoinformatics: recent advances at the interfaces between computer and chemical information sciences, chemistry, and drug discovery. , 2012, Bioorganic & medicinal chemistry.

[21]  Hélène Decornez,et al.  Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. , 2012, Bioorganic & medicinal chemistry.

[22]  J. Keiser,et al.  Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula , 2012, Parasites & Vectors.

[23]  P. Bork,et al.  Drug discovery in the age of systems biology: the rise of computational approaches for data integration. , 2012, Current opinion in biotechnology.

[24]  Ian H. Gilbert,et al.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases , 2012, PLoS neglected tropical diseases.

[25]  C. Andrade,et al.  QSAR and QM/MM approaches applied to drug metabolism prediction. , 2012, Mini reviews in medicinal chemistry.

[26]  Eugene N Muratov,et al.  Existing and Developing Approaches for QSAR Analysis of Mixtures , 2012, Molecular informatics.

[27]  Chuan-Xin Yu,et al.  Thioredoxin Glutathione Reductase as a Novel Drug Target: Evidence from Schistosoma japonicum , 2012, PloS one.

[28]  Adhemar Zerlotini,et al.  A Systematically Improved High Quality Genome and Transcriptome of the Human Blood Fluke Schistosoma mansoni , 2012, PLoS neglected tropical diseases.

[29]  Carolina H Andrade,et al.  Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: fragment-based QSAR and QM/MM docking studies , 2012, Journal of Molecular Modeling.

[30]  Vinicius M. Alves,et al.  Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone , 2012, Journal of Molecular Modeling.

[31]  K. Roy,et al.  Further exploring rm2 metrics for validation of QSPR models , 2011 .

[32]  Anne E Carpenter,et al.  Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software , 2011, Bioinform..

[33]  Q. Bickle,et al.  Comparison of Microscopy and Alamar Blue Reduction in a Larval Based Assay for Schistosome Drug Screening , 2010, PLoS neglected tropical diseases.

[34]  Carolina H Andrade,et al.  Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. , 2010, Bioorganic & medicinal chemistry letters.

[35]  Wolfgang Link,et al.  High content screening: seeing is believing. , 2010, Trends in biotechnology.

[36]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[37]  Minyong Li,et al.  A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. , 2010, European journal of medicinal chemistry.

[38]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[39]  Anton J. Hopfinger,et al.  3D-Pharmacophore mapping of thymidine-based inhibitors of TMPK as potential antituberculosis agents , 2010, J. Comput. Aided Mol. Des..

[40]  Davide Ballabio,et al.  Evaluation of model predictive ability by external validation techniques , 2010 .

[41]  P. Roy,et al.  Roy et al. On Two Novel Parameters for Validation of Predictive QSAR Models. Molecules, 2009, 14, 1660-1701 , 2010, Molecules.

[42]  A. Jadhav,et al.  Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. , 2009, Journal of medicinal chemistry.

[43]  Roberto Todeschini,et al.  Comments on the Definition of the Q2 Parameter for QSAR Validation , 2009, J. Chem. Inf. Model..

[44]  John P. Overington,et al.  The genome of the blood fluke Schistosoma mansoni , 2009, Nature.

[45]  K. Roy,et al.  On Two Novel Parameters for Validation of Predictive QSAR Models , 2009, Molecules.

[46]  A. Miele,et al.  Glutathione reductase and thioredoxin reductase at the crossroad: The structure of Schistosoma mansoni thioredoxin glutathione reductase , 2008, Proteins.

[47]  Anton Simeonov,et al.  Identification of oxadiazoles as new drug leads for the control of schistosomiasis , 2008, Nature Medicine.

[48]  A. Loukas,et al.  New drugs for an ancient parasite , 2008, Nature Medicine.

[49]  Solomon Nwaka,et al.  Schistosomes: challenges in compound screening , 2007, Expert opinion on drug discovery.

[50]  C. Caffrey,et al.  Chemotherapy of schistosomiasis: present and future. , 2007, Current opinion in chemical biology.

[51]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[52]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[53]  Mark T. D. Cronin,et al.  The better predictive model: High q2 for the training set or low root mean square error of prediction for the test set? , 2005 .

[54]  Arthur M. Doweyko,et al.  3D-QSAR illusions , 2004, J. Comput. Aided Mol. Des..

[55]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[56]  G. Coles,et al.  Schistosomiasis control: keep taking the tablets. , 2004, Trends in parasitology.

[57]  Ajay N. Jain,et al.  Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.

[58]  R. Fruttero,et al.  NO donors: Focus on furoxan derivatives , 2004 .

[59]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[60]  S. Wold,et al.  PLS-regression: a basic tool of chemometrics , 2001 .

[61]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[62]  Peter Willett,et al.  Effect of Parameter Variations on the Effectiveness of HQSAR Analyses , 1999 .

[63]  Klaus R. Liedl,et al.  Improving the Predictive Quality of CoMFA Models , 1998 .

[64]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .

[65]  Thorsten Naumann,et al.  HQSAR: A New, Highly Predictive QSAR Technique , 1997 .

[66]  R. Prichard,et al.  Oltipraz-induced decrease in the activity of cytosolic glutathione S-transferase in Schistosoma mansoni. , 1991, International journal for parasitology.

[67]  Svante Wold,et al.  Partial least-squares method for spectrofluorimetric analysis of mixtures of humic acid and lignin sulfonate , 1983 .

[68]  Johann Gasteiger,et al.  A new model for calculating atomic charges in molecules , 1978 .

[69]  Kenneth J. White,et al.  THE DURBIN-WATSON TEST FOR SERIAL CORRELATION WITH EXTREME SAMPLE SIZES OR MANY REGRESSORS' , 1977 .

[70]  William P. Purcell,et al.  A brief review and table of semiempirical parameters used in the Hueckel molecular orbital method , 1967 .

[71]  J. Durbin,et al.  Testing for serial correlation in least squares regression. I. , 1950, Biometrika.